Sven Guenther Net Worth

Sven Guenther biography

Dr. Sven Guenther Ph.D. serves as Executive Vice President - Research and Development of the Company. Dr. Guenther joined our company as our group leader of research in 2007 and served as a member of our board of directors from April 2012 to April 2015, and has served as our executive vice president, research and development since May 2014. Prior to joining our company, Dr. Guenther served as a research scientist for New River Pharmaceuticals from 2003 to 2007. Dr. Guenther received his Ph.D. degree from the University of Iowa.

What is the salary of Sven Guenther?

As the Executive Vice President - Research and Development of Zevra Therapeutics Inc, the total compensation of Sven Guenther at Zevra Therapeutics Inc is $687,731. There are 2 executives at Zevra Therapeutics Inc getting paid more, with Travis Mickle having the highest compensation of $1,360,170.

How old is Sven Guenther?

Sven Guenther is 47, he's been the Executive Vice President - Research and Development of Zevra Therapeutics Inc since 2015. There are 7 older and 5 younger executives at Zevra Therapeutics Inc. The oldest executive at Zevra Therapeutics Inc is Richard W. Pascoe, 57, who is the Exec. Chairman.

What's Sven Guenther's mailing address?

Sven's mailing address filed with the SEC is C/O KEMPHARM, INC., 1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION, FL, 34747.

Insiders trading at Zevra Therapeutics Inc

Over the last 10 years, insiders at Zevra Therapeutics Inc have traded over $0 worth of Zevra Therapeutics Inc stock and bought 3,083,371 units worth $9,282,809 . The most active insiders traders include Street Capital Master Fund,..., David S Tierney et Travis C Mickle. On average, Zevra Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $246,727. The most recent stock trade was executed by R. La Duane Clifton on 13 January 2023, trading 635 units of KMPH stock currently worth $3,689.

What does Zevra Therapeutics Inc do?

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

Zevra Therapeutics Inc executives and stock owners

Zevra Therapeutics Inc executives and other stock owners filed with the SEC include:

• Travis Mickle,
  Chairman of the Board, President, Chief Executive Officer
• Dr. Travis C. Mickle Ph.D.,
  Co-Founder, Pres, CEO & Director
• Sven Guenther,
  Executive Vice President - Research and Development
• R. LaDuane Clifton,
  Chief Financial Officer, Treasurer, Secretary
• Dr. Travis C. Mickle,
  Co-Founder, Chairman, Pres & CEO
• Dr. Sven Guenther,
  Exec. VP of R&D
• R. LaDuane Clifton CPA,
  CFO, Sec. & Treasurer
• Richard W. Pascoe,
  Exec. Chairman
• Jason Rando,
  IR Contact Officer
• David Tierney,
  Independent Director
• Joseph Saluri,
  Independent Director
• Matthew Plooster,
  Independent Director
• Richard Pascoe,
  Lead Independent Director
• Timothy Sangiovanni,
  Vice President, Corporate Controller
• Timothy J. Sangiovanni CPA,
  VP & Corp. Controller
• Dr. Andrew Barrett,
  VP of Scientific Affairs
• Christal M. M. Mickle,
  Co-Founder and VP of Operations & Product Devel.
• Tracy M Woody,
  Chief Commercial Officer
• Danny L Thompson,
  Director
• Gordon K Johnson,
  Chief Business Officer
• Daniel L Cohen,
  EVP, Govt. & Public Relations
• Christal M M Mickle,
  Chief Product Dev. Officer
• Joshua Schafer,
  CCO & EVP, Bus. Development
• Samuel J Braun,
  10% owner
• Tamara A Favorito,
  Director